Stoke Therapeutics Appoints Jennifer Burstein to its Board of Directors

Ms. Burstein brings significant experience in finance for
publicly-traded biotechnology companies

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke
Therapeutics, Inc., a biotechnology company that is pioneering a new
way to treat the underlying cause of genetic diseases by precisely
upregulating protein expression, today announced the appointment of
Jennifer Burstein to its board of directors. Ms. Burstein will join the
audit committee and serve as its chair.


“Jennifer’s significant experience managing financial responsibilities
for publicly-traded biotechnology companies further strengthens our
board of directors,” said Edward M. Kaye, M.D., chief executive officer
of Stoke Therapeutics. “We are confident that her extensive industry
knowledge and deep financial background will support Stoke as the
company continues to mature and we work to pioneer a new way to treat
severe genetic diseases.”


Ms. Burstein most recently served as senior vice president of finance
and principal financial officer at Loxo Oncology, Inc., until its
acquisition by Eli Lilly and Company in January 2019. From 2006 to 2015,
Ms. Burstein held roles of increasing responsibility in finance at
Acorda Therapeutics, Inc., and ultimately served as vice president of
finance for the company from 2010 to 2015. Before that, she worked on
the finance team at Eyetech Pharmaceuticals, Inc., which is currently a
subsidiary of Valeant Pharmaceuticals International, Inc. Earlier in her
career, Ms. Burstein worked in the finance departments at several
companies and in public accounting. She holds a B.S. in business
administration and her MBA in accounting, both from the State University
of New York at Buffalo, and holds a CPA license in New York.


About Stoke Therapeutics


Stoke Therapeutics is a biotechnology company that is pioneering a new
way to treat the underlying causes of severe genetic diseases by
precisely upregulating protein expression to restore target proteins to
near normal levels. Stoke aims to develop the first precision medicine
platform to target the underlying cause of a broad spectrum of genetic
diseases in which the patient has one healthy copy of a gene and one
mutated copy that fails to produce a protein essential to health. These
diseases, in which loss of approximately 50 percent of normal protein
expression causes disease, are called autosomal dominant
haploinsufficiencies. Stoke was launched with investments by Apple Tree
Partners and has raised a total of over $130 million to date through two
financing rounds. Stoke is headquartered in Bedford, Massachusetts with
offices in Cambridge, Massachusetts. For more information visit StokeTherapeutics.com
and follow Stoke on Twitter @StokeTx.


Contacts

Corporate Contact:Dawn KalmarStoke Therapeutics781-303-8302dkalmar@stoketx.com